Dulaglutide trulicity patent expiration?

There isn’t a single “patent expiration” for dulaglutide (Trulicity). It’s protected by multiple patent families plus regulatory data protections, and expiry dates vary by country and by patent type.

Key US point (for context):
- Data exclusivity: As a biologic, dulaglutide enjoys 12 years of data exclusivity from FDA approval. Trulicity was approved in 2014, so the data exclusivity runs through 2026. This can delay biosimilar development even if other patents expire earlier.
- Patents: There are several dulaglutide-related patents (composition, formulation, methods, etc.), and term lengths can be affected by patent-specific expiries and possible extensions. Some may have expired already; others may extend into the mid-to-late 2020s depending on the patent family and any term adjustments.
- Biosimilars: As of the mid-2020s, there were no FDA-approved dulaglutide biosimilars in the US, with competition expectations influenced by both patents and exclusivity.

Global picture:
- Expiry dates differ by jurisdiction. Some countries may see earlier patent expirations; others may have later expirations or additional data/market exclusivities.

If you want, I can look up the current, country-specific expiry dates (for the US or another country) and list the relevant patent families and their status. Let me know which jurisdiction you care about. Also tell me if you’d like me to fetch up-to-date patent data from public patent databases.